IP Library Granted Patent US 11,596,714
Granted Patent B2
US 11,596,714 · App. 17/723,748 · Granted Mar 7, 2023

Methods for development and use of minimally polarized function cell micro-aggregate units in tissue applications using LGR4, LGR5 and LGR6 expressing epithelial stem cells

Inventor: Denver M. Lough (Salt Lake City, UT)
Assignee: POLARITYTE, INC.
A61L27/3813A01N1/021A01N1/0221A61L27/54C12N5/0625A61L2300/412A61L2430/00C12N2513/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,596,714
App. No.
17/723,748
Granted
Mar 7, 2023
Kind
B2
Abstract

Provided herein are constructs of micro-aggregate multicellular, minimally polarized grafts containing Leucine-rich repeat-containing G-protein coupled Receptor (LGR) expressing cells for wound therapy applications, tissue engineering, cell therapy applications, regenerative medicine applications, medical/therapeutic applications, tissue healing applications, immune therapy applications, and tissue transplant therapy applications which preferably are associated with a delivery vector/substrate/support/scaffold for direct application.

Claims (25)

1. A tissue regenerative composition, comprising:

a first tissue section comprising a dermal segment, an epidermal segment, and a segment of a follicular unit of mammalian cutaneous tissue specimen, wherein the dermal segment and the epidermal segment are outside the follicular unit; the segments are interconnected; and

a second tissue section separated from the first tissue section, the second tissue section consisting of a second dermal segment and a second epidermal segment, wherein the second dermal segment and the second epidermal segment are interconnected;

wherein the segment of the follicular unit comprises living LGR-expressing stem cells that are exposed to the second tissue section.

2. The tissue regenerative composition of claim 1 , further comprising a pharmaceutically acceptable cell sustaining media.

3. The tissue regenerative composition of claim 2 , wherein the pharmaceutically acceptable cell sustaining media comprises an antibiotic.

4. The tissue regenerative composition of claim 2 , wherein the pharmaceutically acceptable cell sustaining media comprises an antimyocotic.

5. The tissue regenerative composition of claim 1 , wherein the first tissue section and the second tissue section are substantially devoid of hypodermis.

6. The tissue regenerative composition of claim 1 , wherein the mammalian cutaneous tissue specimen is a human cutaneous tissue specimen.

7. The tissue regenerative composition of claim 1 , wherein the living LGR-expressing stem cells are LGR4-expressing cells, LGR5-expressing cells, LGR6-expressing cells, or any combination thereof.

8. The tissue regenerative composition of claim 1 , wherein the segment of the follicular unit comprises a segment of a bulge.

9. The tissue regenerative composition of claim 1 , wherein the segment of the follicular unit comprises a segment of a bulb.

10. A tissue regenerative composition, comprising:

a tissue section comprising a dermal segment, an epidermal segment, and a segment of a follicular compartment of mammalian cutaneous tissue specimen, wherein the segments are interconnected and the segment of the follicular compartment comprises living LGR-expressing stem cells that are exposed;

wherein the composition is prepared by a process comprising separating fat and hypodermal elements from the mammalian cutaneous tissue specimen ex vivo to provide remaining cutaneous elements containing an epidermal compartment, a dermal compartment, and the follicular compartment; and segmenting the epidermal compartment, the dermal compartment, and the follicular compartment to open the follicular compartment and prepare the tissue section.

11. The tissue regenerative composition of claim 10 , further comprising a second tissue section comprising a second dermal segment and a second epidermal segment, wherein the second dermal segment and the second epidermal segment are interconnected.

12. The tissue regenerative composition of claim 10 , further comprising a pharmaceutically acceptable cell sustaining media.

13. The tissue regenerative composition of claim 12 , wherein the pharmaceutically acceptable cell sustaining media comprises an antibiotic.

14. The tissue regenerative composition of claim 12 , wherein the pharmaceutically acceptable cell sustaining media comprises an antimyocotic.

15. The tissue regenerative composition of claim 10 , wherein the tissue section is substantially devoid of hypodermis.

16. The tissue regenerative composition of claim 11 , wherein the second tissue section is substantially devoid of hypodermis.

17. The tissue regenerative composition of claim 10 , wherein the mammalian cutaneous tissue specimen is a human cutaneous tissue specimen.

18. The tissue regenerative composition of claim 10 , wherein the living LGR-expressing stem cells are LGR4-expressing cells, LGR5-expressing cells, LGR6-expressing cells, or any combination thereof.

19. The tissue regenerative composition of claim 10 , wherein the segment of the follicular compartment comprises a segment of a bulge.

20. The tissue regenerative composition of claim 10 , wherein the segment of the follicular compartment comprises a segment of a bulb.

Assignments (4)
SECURITY INTEREST Recorded May 17, 2024
From: GRANDER ACQUSITION LLC
To: AVENUE VENTURE OPPORTUNITIES FUND, L.P., AS AGENT
Reel/Frame 067452/0616 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 15, 2023
From: POLARITYTE, INC. (PTE); POLARITYTE MD, INC. (PTE MD); POLARITYTE, INC. (PTE NV)
To: GRANDER ACQUISITION LLC
Reel/Frame 064597/0228 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 17, 2023
From: LOUGH, DENVER M, DR.
To: POLARITYTE, INC.
Reel/Frame 063340/0035 →
CHANGE OF ADDRESS Recorded Nov 8, 2022
From: POLARITYTE, INC.
To: POLARITYTE, INC.
Reel/Frame 061900/0204 →
Continuity (5)
Continuation 17326734 · May 21, 2021
Continuation 15650656 · Jul 14, 2017
Division 14954335 · Nov 30, 2015
Provisional Application 62086526 · Dec 2, 2014
Related Publication 20220241464A1 · Aug 4, 2022